CXCL8 and neoplasm: The potential of CXCL8 as a therapeutic target is underscored by the fact that an anti‐CXCL8 monoclonal antibody can enhance antitumour immunity in triple‐negative breast cancer and inhibit the recruitment of neutrophils into the tumour.